Microbiota metabolites: Pivotal players of cardiovascular damage in chronic kidney disease
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
In chronic kidney disease (CKD), cardiovascular (CV) damage is present in parallel which leads to an increased risk of CV disease. Both traditional and non-traditional risk factors contribute to CV damage in CKD. The systemic role of the microbiota as a central player in the pathophysiology of many organs is progressively emerging in the literature: the microbiota is indeed involved in a complex, bi-directional network between many organs, including the kidney and heart connection, although many of these relationships still need to be elucidated through in-depth mechanistic studies. The aim of this review is to provide evidence that microbiota metabolites influence non-traditional risk factors, such as inflammation and endothelial dysfunction in CKD-associated CV damage. Here, we report our current understanding and hypotheses on the gut-kidney and gut-heart axes and provide details on the potential mechanisms mediated by microbial metabolites. More specifically, we summarize some novel hypotheses linking the microbiota to blood pressure regulation and hypertension. We also emphasise the idea that the nutritional management of CKD should be redesigned and include the new findings from research on the intrinsic plasticity of the microbiota and its metabolites in response to food intake. The need is felt to integrate the classical salt and protein restriction approach for CKD patients with foods that enhance intestinal wellness. Finally, we discuss the new perspectives, especially the importance of taking care of the microbiota in order to prevent the risk of developing CKD and hypertension, as well as the still not tested but very promising CKD innovative treatments, such as postbiotic supplementation and bacteriotherapy. This interesting area of research offers potential complementary approaches to the management of CKD and CV damage assuming that the causal mechanisms underlying the gut-kidney and gut-heart axes are clarified. This will pave the way to the design of new personalized therapies targeting gut microbiota.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sacks, F. M., Svetkey, L. P., Vollmer, W. M., Appel, L. J., Bray, G. A., Harsha, D., Obarzanek, E., Conlin, P. R., Miller, E. R., Simons-Morton, D. G., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200101043440101 · Cited by 5,638
Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis
Koeth, R. A., Wang, Z., Levison, B. S., Buffa, J. A., Org, E., Sheehy, B. T., Britt, E. B., Fu, X., Wu, Y., Li, L., et al. (2013) · Nature Medicine · doi:10.1038/nm.3145 · Cited by 4,386
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
Gansevoort, R. T., Correa-Rotter, R., Hemmelgarn, B. R., Jafar, T. H., Heerspink, H. J. L., Mann, J. F., Matsushita, K., & Wen, C. P. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60595-4 · Cited by 2,213
Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk
Zhu, W., Gregory, J. C., Org, E., Buffa, J. A., Gupta, N., Wang, Z., Li, L., Fu, X., Wu, Y., Mehrabian, M., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.011 · Cited by 1,968
Gut Dysbiosis Is Linked to Hypertension
Yang, T., Santisteban, M. M., Rodriguez, V., Li, E., Ahmari, N., Carvajal, J. M., Zadeh, M., Gong, M., Qi, Y., Zubcevic, J., et al. (2015) · Hypertension · doi:10.1161/hypertensionaha.115.05315 · Cited by 1,478 · cited 2×
“Some human and animal studies indeed showed that hypertension and atherosclerosis associate with a decrease in microbiota diversity and richness, alteration in its composition and in the microbial metabolic profile [6].”
BackgroundTang, W. H. W., Wang, Z., Kennedy, D. J., Wu, Y., Buffa, J. A., Agatisa-Boyle, B., Li, X. S., Levison, B. S., & Hazen, S. L. (2015) · Circulation Research · doi:10.1161/circresaha.116.305360 · Cited by 1,223 · cited 2×
“Accumulating evidence in the literature indicates a role for elevated TMAO levels as an indicator of increased risk of all-cause mortality in CKD patients [68].”
BackgroundEuropean consensus conference on faecal microbiota transplantation in clinical practice
Cammarota, G., Ianiro, G., Tilg, H., Rajilić-Stojanović, M., Kump, P., Satokari, R., Sokol, H., Arkkila, P., Pintus, C., Hart, A., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-313017 · Cited by 1,207
Pluznick, J. L., Protzko, R. J., Gevorgyan, H., Peterlin, Z., Sipos, A., Han, J., Brunet, I., Wan, L.-X., Rey, F., Wang, T., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1215927110 · Cited by 1,191 · cited 1×
“Activation of different SCFA receptors present at renal level, such as Olfr78, Gpr41 or Gpr43, antagonistically results in raised or decreased BP [78].”
BackgroundChronic kidney disease alters intestinal microbial flora
Vaziri, N. D., Wong, J., Pahl, M., Piceno, Y. M., Yuan, J., DeSantis, T. Z., Ni, Z., Nguyen, T.-H., & Andersen, G. L. (2013) · Kidney International · doi:10.1038/ki.2012.345 · Cited by 1,164 · cited 2×
“other hand, it is the same uremic status that induces a shift in the gut microbial metabolism and composition [16], and the resulting dysbiosis is often worsened, especially in advanced CKD, by the current nutritional management which is characterized by a drastic fiber restriction that favours the proteolytic imbalan…”
BackgroundSeldin, M. M., Meng, Y., Qi, H., Zhu, W., Wang, Z., Hazen, S. L., Lusis, A. J., & Shih, D. M. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002767 · Cited by 911 · cited 1×
“focused on the involvement of TMAO in atherosclerotic plaque development in animal models, showing a critical role for TMAO in increasing macrophage cholesterol accumulation and foam cell formation [70], enhancing human platelets hyper-reactivity, and enhancing in vivo thrombosis [71] or by a pro-inflammatory action […”
Background
Cited by
The Klotho proteins in health and disease
Kuro-o, M. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0078-3 · Cited by 707
Postbiotics: metabolites and mechanisms involved in microbiota-host interactions
Peluzio, M. D. C. G., Martinez, J. A., & Milagro, F. I. (2021) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2020.12.004 · Cited by 139
Kuro-o, M. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy126 · Cited by 80
Kim, K., Jang, H., Kim, E., Kim, H., & Sung, G. Y. (2023) · Experimental Dermatology · doi:10.1111/exd.14940 · Cited by 24
Metadata
- Authors
- Cosola, C., Rocchetti, M. T., Cupisti, A., & Gesualdo, L.
- Venue
- Pharmacological Research
- Publisher
- Elsevier BV
- Published
- 2018-04
- Volume
- 130
- Pages
- 132-142
- ISSN
- 1043-6618 (ISSN-L)
- OpenAlex
- W2791230288
- Cited by
- 97
- References
- 22
- FWCI
- 3.92
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Microbiota metabolites: Pivotal players of cardiovascular damage in chronic kidney disease. https://app.cochat.ai/papers/10.1016/j.phrs.2018.03.003
- The paper
- Cosola, C., Rocchetti, M. T., Cupisti, A., & Gesualdo, L. (2018). Microbiota metabolites: Pivotal players of cardiovascular damage in chronic kidney disease. Pharmacological Research. https://doi.org/10.1016/j.phrs.2018.03.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.